Wed, Jul 9, 2014, 10:51 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

skeeta_bug 44 posts  |  Last Activity: Jun 2, 2014 1:15 PM Member since: Nov 22, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Skeeta Bug thinking about having a delisting contest to see if anyone can guess what month this gets delisted. Skeeta Bug will give a hint. Sometime this year. A virus that is incapable of killing cancer. Enjoy this board while you can, not gonna be around much longer.

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • skeeta_bug skeeta_bug May 29, 2014 10:29 AM Flag

    Stick a fork in it, its well past done. Just like everything else here, herpes and adenovirus patents expire in 5 years, oncy other patents expiring in 3 years and accelerating rapidly. A virus that is incapable of killing cancer, a cash position dwindling. Not looking good.

    The best thing that could happen right now is to dissolve this and give each shareholder roughly 18 cents per share or whatever that ammounts to before each shareholder gets 0 cents per share.

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • skeeta_bug skeeta_bug May 27, 2014 10:57 AM Flag

    Skeeta Bug checking it out and taking a rough quick look at patent expirations. 7 patents expire in 3 years and then it rapidly accelerates. At first glance it looks that half or so of the patents are within 8 years of expiring. Once the patent expirations begins talk about acceleration. Skeeta bug putting together a rough patent accelerated expiration yearly table. IP assets depreciation accelerating rapidly.

    Skeeta Bug Likes it.

    Sentiment: Strong Sell

  • skeeta_bug skeeta_bug May 26, 2014 2:48 PM Flag

    Skeeta Bug checked it out and of course oncolytics accelerated patent expirations are actually a lot worse than the 2007 annual information form on Sedar. oncolytics patent expirations actually begin next year. Maybe Bailey can help Skeeta Bug out and update the patent expiration dates of oncolytics IP portfolio.
    Doesnt oncolytics accelerated patent expiration begin next year with 4 patent expirations in 2015?

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • Bailey, can you help Skeeta Bug out, isnt oncys very limited almost nonexistent herpes/adenovirus IP begin expiring in 5-6 years depending on which country the patent has been approved.

    oncy hasnt even done a phase 1 trial regarding the above and the patents are approaching expiration. What value do you attribute to a patent portfolio with accelerating expirations?

    Skeeta Bug Likes it.

    Sentiment: Strong Sell

  • skeeta_bug skeeta_bug May 26, 2014 10:58 AM Flag

    Skeeta Bug went and checked it out and bailey should check this out. He likes to tout accelerated approval but what is really accelerating is the expiration of patents. Skeeta Bug checked out oncys annual information form Mar 2, 2007 on sedar and sees lots of patents expiring never mind one. Over the next 5 years, 5 patents expire and then talk about acceleration. At least 4 patents expire continiously yearly after that. Also these are only select patents as noted: The actual patents expiring are probably double as they are all not listed.



    Skeeta Bug Likes It.

    known patent expirations.

    2017-1
    2018-3
    2019-1
    2020-4
    2021-7
    2022-4
    2023-4

    Sentiment: Strong Sell

  • The value is deteriorating rapidly with a failed virus incapable of killing cancer, an IP portfolio that begins expiring in three years, a cash position that is disappearing. Not looking good.

    Skeeta Bug Likes it.

    Sentiment: Strong Sell

  • skeeta_bug skeeta_bug May 23, 2014 5:19 PM Flag

    Skeeta Bug has said History just keeps repeating itelf. Remember Synsorb, didnt they do a share consolidation once or twice where shareholders received 1 share for every 8 shares of synsorb held? That is the only way this has any chance of moving up in price unfortunately it wont be of any benefit to shareholders. At an increased share price, Thompsons million plus warrants become in the money. Does it look like that is the sole purpose of this exercise which in the end will not likely come to fruition anyway?

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • Oh Yeah Baby, Skeeta Bug Likes it, all the long suffering shareholders who have suffered for 12 plus years look like they are finally going to get what they wanted a takeover. Unfortunately it wont turn out well for them.

    From Management Information Circular, May 9, 2014 on Sedar:

    Sale Transaction Bonus Pool

    In addition to the annual compensation paid to the CEO, COO and CFO, in an effort to maximize value for the
    Corporation's shareholders, the Board has approved the recommendation from the Compensation Committee that a
    Sales Transaction Bonus ("STB") be created in the event of a sale transaction. A STB pool would be created based
    on a scale between 1% - 2.5% of the Corporation's market capitalization for a sale transaction with a transaction price
    over $7.50 per share. The STB pool would be calculated as the sum of:
    a. for a Transaction Price of $7.51 to $10.00, the Transaction Price minus $7.50, multiplied by 0.010;
    b. plus for a Transaction Price of $10.01 to $15.00, the Transaction Price minus $10.00, multiplied by 0.015;
    c. plus for a Transaction Price of $15.01 to $20.00, the Transaction Price minus $15.00, multiplied by 0.020;
    d. plus for a Transaction Price of $20.01 and higher, the Transaction Price minus $20.00, multiplied by 0.025
    multiplied by the number of common shares outstanding at that time.
    The STB pool would be split between the CEO (45%), COO (35%) and CFO (20%).

    Sentiment: Strong Sell

  • Reply to

    Oncyscam patents start expiring in 3 years.

    by skeeta_bug May 20, 2014 8:53 PM
    skeeta_bug skeeta_bug May 23, 2014 12:12 AM Flag

    From sedar, oncolytics annual information form

    Patent Number U.S. 6,110,461
    Reovirus for the Treatment of
    Neoplasia
    Oncolytics Biotech Inc. Dr. Patrick W.K. Lee
    Dr. James E. Strong
    Dr. Matthew C. Coffey
    Filing date:Aug. 13, 1997
    Issued:Aug. 29, 2000

    Like Skeeta Bug said the patents begin expiring in only 3 years starting in 2017. Not that their worth anything anyway because like Adam Feuerstein said "3. Oncolytics Biotech(ONCY_): In my opinion, management has worked hard to delay and hide as much Reolysin data as possible because the experimental cancer-killing virus is incapable of killing cancer at all. "

    Skeeta Bug thinks the patents are worthless anyway because the virus is incapable of killing cancer at all but even if you disagree with Skeeta Bug and think there is value to the patents, they begin expiring shortly.

    Any thoughts.

    Sentiment: Strong Sell

  • Reply to

    news release

    by inthno57 May 21, 2014 7:36 PM
    skeeta_bug skeeta_bug May 21, 2014 10:48 PM Flag

    d2foxes, How many times have you heard Skeeta Bug say Amazing how history keeps repeating itself for Thompsons failed companies. Go back and look what Thompson did when Synsorb started going under. That will give you some ideas of where oncyscam is going.

    Trust Skeeta Bug, History is repeating itself.

    Everything is right in front of your face if want to see it. Read over the credentials of the two new directors and then go back and read Synsorb ala patents, bcy lifesciences, Transition Therapeutics, etc.etc.

    Skeeta Bug gonna have a heyday saying Amazing how history keeps repeating itself. Unfortunately for the shareholders, history also keeps repeating itself.

    Skeeta Bug Likes it

    Sentiment: Strong Sell

  • Reply to

    news release

    by inthno57 May 21, 2014 7:36 PM
    skeeta_bug skeeta_bug May 21, 2014 10:24 PM Flag

    Probably the only time Skeeta Bug will agree with Bailey. Yes there is a merger and acquisition in oncyscams future. oncyscam will likely get taken over in the near future over which some company will be able to take advantage of oncyscam tax losses. The writing is on the wall. Their credentials definitely point oncyscam to follow in the tradition of other failed Thompson companies. However, when oncyscam gets taken over, the only value left will be tax losses to a prospective takeover company. Not much value with a failed virus incapable of killing cancer at all.

    Brad Thompson was the CEO of Synsorb and Genescape which later evolved somehow to become oil & gas companies to take advantage of tax losses.

    Amazing how history just keeps repeating itself.

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • Reply to

    Guaranteed way to become rich with ONCY

    by mike_ensign May 21, 2014 9:04 PM
    skeeta_bug skeeta_bug May 21, 2014 9:11 PM Flag

    Or a Guaranteed way to become POOR with oncyscam, go long and waste 12 years of your life pumping this failed virus that is incapable of killing cancer at all.

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • Not that it matters because oncyscam will in all likelihood be an oil and gas company within 3 years just like Synsorb but oncyscams patents start expiring in 3 years. If it makes the DNGI's feel any better, you can go and read Baileys post about accelerated approval. Not gonna happen but it will help you feel better until, one day you wake up and oncyscam is no more. What is accelerated right now is the demise of oncyscam.

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • skeeta_bug skeeta_bug May 20, 2014 8:43 PM Flag

    Come on now, somebody must have some thoughts about this. Check out all of these Thompson Failures, Synsorb, oncyscam, Transition Therapeutics, Genescape, Wavepoint, Haywood Lifesciences, Amma Corp, Organetix, Signalgene, BCY Lifesciences. What a resume

    Remember there is an asterisk by Transition Theraputics. Transition still seem to be thriving and hasnt failed like all the other Thompson companies. According to conjob, oncyscam did a share swap with Transition and lost 2 million dollars on the deal to prevent a takeover. Meanwhile if oncyscam had held onto the shares they would be worth approximately 35 million dollars today.

    When oncyscam goes under and is worth nothing, just think if oncyscam had held onto their Transition shares, at least they would have held some value. Any thoughts.

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • Reply to

    Virus is Incapable of Killing Cancer At All

    by skeeta_bug May 19, 2014 12:26 AM
    skeeta_bug skeeta_bug May 20, 2014 12:07 PM Flag

    No AF is NOT wrong when he says Reo has no effect at all as evidenced not only by the failed Head-and-Neck fiasco but others.

    Read Skeeta Bugs post regarding the failed sarcoma trial:

    hXXp://www.investorvillage.com/mbthread.asp?mb=3507&tid=4497126&showall=1

    and read the famed scientist Matdum pumping the scam.

    hXXp://www.investorvillage.com/mbthread.asp?mb=3507&tid=4506105&showall=1

    Replace XX with tt in the preceding. Skeeta Bug been gone away a long time and not sure if yahoo will allow the links.

    Sentiment: Strong Sell

  • Reply to

    Virus is Incapable of Killing Cancer At All

    by skeeta_bug May 19, 2014 12:26 AM
    skeeta_bug skeeta_bug May 20, 2014 10:06 AM Flag

    Great call by Adam predicting thatoncyscam will end 2013 lower because the reolysin is incapable of killing cancer at all. The ugly truth about Reolysin cant be hidden forever and he was also bang on that the head-and-neck trial was a total bust.

    Poor scammers, Remember what Jack Nicholson said: "You Cant Handle The Truth" Reolysin is a scam as evidenced by continued failed trials.

    Skeeta Bug Likes It.

    Sentiment: Strong Sell

  • Reply to

    Matdum's Umbilical Cord

    by skeeta_bug May 20, 2007 9:00 PM
    skeeta_bug skeeta_bug May 19, 2014 7:28 PM Flag

    ha,ha, ha, ha, Skeeta just wet his pants again. Matdums/Geniemans umbilical cord was the message board to fraud, scientifiic scamming, treasure chest of pearls and Matdum kept this little scret to himself because no one would believe the story and the failed trials that oncyscam and DNDN DNGI's have been through.

    Skeeta Bug forgot about matdum/genieman scamming DNDN DNGI's. Skeeta Bugs been away 6 years and just checked out DNDN.

    Skeeta Bug Likes It. Oncyscam so funny.

    Sentiment: Strong Sell

  • skeeta_bug skeeta_bug May 19, 2014 7:20 PM Flag

    As per Adams post about the trial:

    "The study has no control arm, making results clinically meaningless."

    or as iwfal replied to matdum/genieman on the i-hub board:

    "If the protocol really is as complex as you wrote up previously and the company isn't completely tranarent it is a ripe opportunity for abusing shareholders. ONCY in particular has a
    long history of questionable underpowered single arm trials without an obvious result so I would be dubious of anything but complete transparency. "

    Amazing History just keeps repeating itself. Where have you heard that before. Another trial without an obvious result that the fraudsters pump like theres no tomorrow. Keep Thoughtless Momentum Going

    Skeeta Bug Likes it.

    Sentiment: Strong Sell

  • skeeta_bug skeeta_bug May 19, 2014 5:03 PM Flag

    cntd:

    Primary Outcome Measures: •Complete response (CR) and partial response (PR) as well as prolonged stabilization of disease (SD) will be considered indicative of response. RECIST criteria will be utilized to assess radiographic response. [ Time Frame: For PR or CR, changes in tumor measurements must be confirmed 4 weeks after the criteria for response are first met. For SD, follow-up measurements must have met the SD criteria at least once after trial entry at a minimum interval of 12 weeks. ] [ Designated as safety issue: No ]


    Secondary Outcome Measures: •Safety data, including laboratory parameters and adverse events, will be collected for all patients in order to determine the qualitative and quantitative toxicity, and reversibility of toxicity, of REOLYSIN. [ Time Frame: within 30 days of the last dose of REOLYSIN ] [ Designated as safety issue: Yes ]


    Stable disease to repeat is not a true response but oncySCAM counts it as such. Roche doesn't even include such a weak endpoint as Stable Disease in their Phase II Sarcoma trial.

    Skeeta Bug knows if BigDennis were here, he would say, Big Pharma would terminate the trial.


    Meanwhile the scammers pump it like there's no tomorrow. Any naive investors to scam.


    Meanwhile when the oncySCAM Phase II sarcoma trial is over and done with, Skeeta Bug knows there will be perplexed naive investors who are wondering why oncySCAM is not progressing to Phase III.


    Skeeta Bug Likes it. Any thoughts?

    Sentiment: Strong Sell

ONCY
1.66+0.12(+7.79%)Jul 9 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.